Author Archives: BNS Staff

Pulmonary Arterial Hypertension Medications Studied for Drug Interactions

According to a study published by researchers at Novartis Pharma, common medications for severe pulmonary arterial hypertension interact, increasing one another’s levels when taken at the same time. However, co-administration of the medications does not appear to impact their effectiveness or increase the risk of liver problems. The study,…

Raising Pulmonary Hypertension Awareness Through Art

Funding and awards from disease advocacy groups are usually given to scientists or clinicians and earmarked for research on new therapies and treatment options. While the Pulmonary Hypertension Association (PHA) is certainly well-known for funding research into PH, the organization is also passionate about empowering patients…

FDA Postmarket Trial for PAH Treatment Bosentan Reveals Drug Does Not Reduce Time To Mortality Rates

Drug maker Actelion has indicated that the company’s Food and Drug Administration (FDA)–approved pulmonary arterial hypertension (PAH) drug Bosentan, which is also known under the brand names of Actelion and Tracleer, recently failed a key FDA postmarket test. The test, which was part of the postmarket COMPASS 2 trial, revealed that Bosentan did not reduce time…

Early-Stage Pulmonary Arterial Hypertension Therapy From Pulmokine Awarded $1.5 Million Through Federally Funded VITA Contract

Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…